by James Radke, PhD | Jan 29, 2023
The U.S. Food and Drug Administration (FDA) has approved zanubrutinib (Brukinsa) to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow, lymph nodes,...
by James Radke, PhD | Jan 4, 2023
Adeline Vanderver, MD, Program Director of the Leukodystrophy Center in the Division of Neurology at Children’s Hospital of Philadelphia (CHOP), Professor of Neurology and Pediatrics, Perelman School of Medicine of the University of Pennsylvania, and Jacob A....
by James Radke, PhD | Dec 16, 2022
Alan M. Mendelsohn, MD, Chief Medical Officer at Timber Pharmaceuticals, provides an overview of congenital ichthyosis. As Dr. Mendelsohn explains, congenital ichthyosis is a rare genetic skin disorder. It is characterized by dry, thickened, and scaling...
by James Radke, PhD | Dec 14, 2022
Guillaume Canaud, MD, PhD, of Necker-Enfants Malades Hospital – AP-HP, the Paris Descartes University, provides an overview of PiK3CA-related overgrowth syndrome (PROS) and explains why it is important to regularly measure objective outcomes in persons with...
by James Radke, PhD | Dec 12, 2022
Molly Tokaz, MD, from Fred Hutchinson Cancer Center, and Lisa Force, MD, MPH, from University of Washington School of Medicine, discuss the recent analysis of worldwide utilization of hematopoietic stem cell transplantation (HSCT) for the treatment of acute...
